Executive Committee

The members of the Executive Committee are appointed by the Board of Directors. Lonza’s Executive Committee performs the duties assigned to it by the Board of Directors under the terms of the Regulations Governing Internal Organization and Board Committees. It is responsible for managing Lonza worldwide and for implementing policies and strategies as defined by the Board of Directors. The Executive Committee supports and coordinates the activities of the segments, the corporate functions and the global business service organization. The Executive Committee is also responsible for leadership development.

Pierre-Alain Ruffieux, PhD

Chief Executive Officer (CEO) and Member of the Executive Committee (since November 2020)
Pierre-Alain Ruffieux holds a doctorate in Biotechnology and a master’s degree in Chemical Engineering and Biotechnology from the Swiss Federal Institute of Technology (EPFL), Lausanne (CH).

Former Activities and Functions
  • Head of Global Pharma Technical Operations & Member Pharma Executive Team, F. Hoffmann-La Roche (2017–2020)
  • Head of Quality and Compliance, Global Pharma Technical Operations, F. Hoffmann-La Roche (2015–2017)
  • Head of Quality, Pharmaceutical Division & Member Pharmaceutical Executive Committee, Novartis Pharmaceuticals (2012–2015)
  • Head of Global Pharma Technical Operations & Biologics Quality Assurance, Novartis Pharmaceuticals (2010–2012)
  • Global Head of Quality for Biopharmaceutical, Novartis Pharmaceuticals (2009–2010)
  • Various positions in technical development and manufacturing at Novartis Pharmaceuticals & Sandoz, Novartis Group (2003–2009)
  • Various positions in technical development and manufacturing at Serono (now Merck Serono) (1998–2003)

Philippe Deecke

Chief Financial Officer (CFO) and Member of the Executive Committee (since December 2021)
Philippe holds a Master’s Degree in Industrial Management and Manufacturing and a Bachelor’s Degree in Computer Science from the Swiss Federal Institute of Technology (ETH), Zürich (CH), as well as an MBA from Cornell University’s Johnson School (US).

Former Activities and Functions
  • Chief Financial Officer and Member of the Executive Committee, Lonza Group Ltd (2021)
  • CFO, Novartis Oncology (2021)
  • CFO, Sandoz, division of Novartis (2017–2021)
  • CFO, Alcon EMEA, division of Novartis (2015–2017)
  • Head Group Business planning and Alaysis, Novartis International AG (2012–2015)
  • CFO, Chief Financial and Administration Officer, Novartis Schweiz AG (2010–2012)
  • Project Director, Novartis International AG (2008–2010)
  • Head Finance, Novartis Pharmaceutical Inc. (US)  (2006–2008)
  • Assistant to CEO, Novartis International AG (2005–2006)
  • Associate Principal, McKinsey (1998–2005)

Caroline Barth

Chief Human Resources Officer (CHRO) and Member of the Executive Committee (since May 2020)
Caroline Barth holds a degree in European Business Studies from the University of Sunderland (UK) and an MBA from The Open University, Brussels (BE).

Former Activities and Functions
  • Global Head of Human Resources, Pharma, Novartis Pharma AG (2016–2020)
  • Global Head Pharma Strategy, Novartis Pharma AG (2019)
  • Global Head of Human Resources, Pharma Manufacturing and Quality, Novartis Pharma AG (2014–2016)
  • Global Head of Human Resources, Central & Eastern Europe, Novartis Pharma AG (2013–2014)
  • VP, Human Resources Canada Pharma & Corporate HR Leader, Novartis Pharma AG (2010–2013)
  • Head of Talent Management, Organizational Development & Staffing, Europe, Novartis Pharma AG (2008–2010)
  • Head of Human Resources Global IT, Novartis Pharma AG (2006–2008)
  • Human Resources Integration Leader, Novartis Pharma AG (2004–2006)
  • HR Communications Leader, EMEA & APAC, Cisco Systems (2001–2003)
  • HR Generalist, Emerging Markets, Cisco Systems (1997–2001)

Stefan Stoffel

Head, Group Operations (since January 2021) and Member of the Executive Committee (since March 2019)
Stefan Stoffel holds a degree in engineering from Lucerne University of Applied Sciences and Arts (CH).

Former Activities and Functions
  • Head of Lonza Pharma & Biotech Strategic Growth Investments and Ibex® Solutions (2016–2019)
  • Head of Lonza Pharma & Biotech Operations (2013–2016)
  • General Manager of Lonza Chemical Operations Business Unit (2010–2013)
  • Head of Lonza’s Small Molecules Exclusive Synthesis Business Unit (2009–2010)
  • Head of Operations for Lonza’s Small Molecules Exclusive Synthesis Business Unit (2007–2009)
  • Various positions at Lonza in Engineering & Maintenance, Technical Management, Production and Operations Management for Lonza AG and Lonza Inc. (1991–2007)
Claude Dartiguelongue

President, Capsules & Health Ingredients Division (since January 2020) and Member of the Executive Committee (since April 2021)
Claude Dartiguelongue holds a master’s degree in Medical Management from the Ecole Superieure de Commerce de Paris, ESCP (FR), as well as in Biotechnology from the University of Grenoble (FR).

Former Activities and Functions
  • President, Microbiology, Thermo Fisher Scientific (2016 – 2019)
  • President, BioSciences, Becton, Dickinson and Company (BD) (2013 – 2016)
  • President, Pharmaceutical Systems, BD (2009 – 2012)
  • Regional and global leadership positions (primarily in Sales and Marketing), BD (2002 – 2009)

Gordon Bates

President, Small Molecules Division (since January 2021) and Member of the Executive Committee (since April 2021)
Gordon Bates holds a master’s degree in Engineering Business Management from the University of Warwick (UK).

Former Activities and Functions
  • President, Lonza Chemical Division (2018 – 2020)
  • Senior Vice President, Business Unit Head, Lonza Chemical and Microbial Manufacturing (2015 – 2017)
  • Global Head of Sales, Lonza Pharma Custom Manufacturing (2013 – 2015)
  • Head of Operations and Site Manager, Lonza Slough (UK) (2007 – 2013)
  • Global Head of Lonza Operational Excellence (2003 – 2007)

Jean-Christophe Hyvert

President, Biologics and Cell & Gene Divisions (since January 2021) and Member of the Executive Committee (since April 2021)
Jean-Christophe Hyvert holds a master’s degree in Physics from INSA, Rennes (FR) and an MBA from the Northwestern University (USA).

Former Activities and Functions
  • Chief Commercial Officer, Lonza Pharma Biotech & Nutrition Segment (2019 – 2020)
  • Vice President, Finance, Lonza Pharma & Biotech Segment (2017 – 2019)
  • Finance Director ECEMEA, Baxter International (2016 – 2017)
  • Senior Director EMEA Business Development, Baxter International (2015 – 2016)
  • Finance Director, Baxter International (2013 – 2014)
  • Various leadership positions in Finance and Operations at Newell Rubbermaid, Lehman Brothers and Legris (covering Corporate Development, M&A and Supply Chain) (1995 – 2013)